Semaglutide vs liraglutide has direct randomized evidence from STEP 8. That is more informative for its particular question than comparing unrelated trials. It still requires the studied formulations, population, duration, discontinuations and safety findings to remain beside the weight-change result.
What STEP 8 compared
The 2022 STEP 8 publication enrolled 338 adults with overweight or obesity without diabetes and followed the trial comparison for 68 weeks. It compared specified semaglutide and liraglutide interventions alongside dietary and physical-activity counselling. The active-treatment comparison was open-label, while matched placebo comparisons had their own blinding arrangements.
The trial reported greater mean percentage weight reduction with semaglutide than liraglutide in that setting. The headline does not remove the importance of the complete intervention and participant criteria.
Read outcomes and participant accounting together
Scroll horizontally to read all columns.
| Trial detail | Why it belongs beside the result |
|---|---|
| Randomized population | Defines who the comparison represents |
| Open-label active comparison | Can influence behaviour and expectations |
| 68-week endpoint | Defines the observation period |
| Treatment discontinuation | Affects how the treatment experience is understood |
| Adverse events | A weight outcome alone is not the whole clinical comparison |
Mean weight change was reported as −15.8% with semaglutide and −6.4% with liraglutide, a difference of 9.4 percentage points. A group mean is not an individual prediction. Gastrointestinal events were common in both groups, and discontinuation patterns also differed.
Why percentage points matter
Subtracting two percentage changes produces a percentage-point difference. Calling that difference simply “9.4% better” can be ambiguous, because relative and absolute percentage comparisons are not the same arithmetic.
For a hypothetical comparison of 10% and 5%, the absolute difference is five percentage points, while the first value is twice the second. Neither description should be substituted for the other without saying which calculation is meant.
Do not replace the direct trial with unrelated averages
The STEP 1 trial is useful semaglutide evidence, but it does not provide the same active comparison as STEP 8. Separate publications may differ in participants, missing-data handling and other design details. A directly randomized question and an indirect cross-trial comparison should be labelled differently.
Read semaglutide versus tirzepatide for another comparison with its own evidence base. The ingredient pair determines which source is relevant.
Clinical comparison is not a switching instruction
The Canadian Ozempic monograph and product database concern exact finished medicines and their authorizations. STEP 8 does not establish equivalence between every product sold under the ingredient names, nor does it supply an individual switching plan.
For molecular background, use the semaglutide and liraglutide dossiers. This article explains a trial, without selecting treatment or providing dosing conversions.
